Article

Dr. George Addresses Provider Issues Regarding Immunotherapies

Conference|ASCO: American Society of Clinical Oncology

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer. He says that when the drug first came on the market many administrative challenges existed. There were limited access and associated reimbursement issues due to the limited production capabilities. However, Dr George states that currently there are no issues with payer coverage with little to no delays when it comes to prescribing the agent.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Related Videos
Mike Fazio, Navista, Cardinal Health
Dr Mingyang Song
Dr K. Vish Viswanath
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
Dr Kimlin Tam Ashing
Dr John Heymach
Julia Logan
Dr John Heymach
Julia Logan
Related Content
The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com
April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser
Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
COA signage | Image Credit: © Maggie L. Shaw
April 29th 2025

Advancing the Art of Medicine Through Partnership

Maggie L. Shaw
Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.
managed care cast logo
November 27th 2024

Operationalizing Bispecifics in Multiple Myeloma

Mary Caffrey Laura Joszt, MA
Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.
Alopecia areata. | Image Credit: cattyphoto - stock.adobe.com
April 29th 2025

Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata

Cameron Santoro
Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.
The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
April 29th 2025

New Developments Warrant Rethinking HCC Transplant Criteria

Jared Kaltwasser
Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo